Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer

Cancer Science

Volumn 105, Issue 2, 2014, Pages 150-158

  Huang, Xiao Mei ^a   Liu, Xiao Sun ^a   Lin, Xian Ke ^a   Yu, Hang ^a   Sun, Jian Yi ^a   Liu, Xiao Kun ^a   Chen, Chao ^a   Jin, Hai Long ^a   Zhang, Ge Er ^a   Shi, Xiao Xiao ^a   Zhang, Qing ^a   Yu, Ji Ren ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Dendritic cells; Immune defense suppression; Regulatory T cells; Stomach neoplasms; Tumor escape

Indexed keywords

INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BLOOD; CANCER CELL; CANCER PATIENT; CANCER TISSUE; CELL FUNCTION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STOMACH CARCINOMA; STOMACH MUCOSA; TUMOR MICROENVIRONMENT;

DENDRITIC CELLS; IMMUNE DEFENSE SUPPRESSION; REGULATORY T CELLS; STOMACH NEOPLASMS; TUMOR ESCAPE;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNE TOLERANCE; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; INTERFERON-ALPHA; INTERLEUKIN-10; MALE; MIDDLE AGED; STOMACH NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84893782730     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12327     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2002; 61: 69-90.
2. th century: a period analysis. Lancet 2002; 360: 1131-5.
3. Brenner H, Stegmaier C, Ziegler H. Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium. Ann Oncol 2005; 16: 981-6.
4. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+ CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98: 1089-99.
5. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9: 4404-8.
6. Shen Y, Qu QX, Zhu YB, Zhang XG. Analysis of CD8 + CD28- T-suppressor cells in gastric cancer patients. J Immunoassay Immunochem 2012; 33: 149-55.
7. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-87.
8. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-61.
9. Miller AM, Lundberg K, Ozenci V et al. CD4 + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398-405.
10. Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-72.
11. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
12. Ito T, Hanabuchi S, Wang YH et al. Two functional subsets of FOXP3 + regulatory T cells in human thymus and periphery. Immunity 2008; 28: 870-80.
13. Chen Y, Shen S, Gorentla BK, Gao J, Zhong XP. Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression. J Immunol 2012; 188: 1698-707.
14. Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL. Expression of ICOS on human melanoma-infiltrating CD4 + CD25highFoxp3 + T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008; 180: 2967-80.
15. Chen YL, Fang JH, Lai MD, Shan YS. Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma. World J Gastroenterol 2008; 14: 5797-809.
16. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010; 1183: 89-103.
17. Zou W, Machelon V, Coulomb-L'Hermin A et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 1339-46.
18. Treilleux I, Blay JY, Bendriss-Vermare N et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10: 7466-74.
19. Ito T, Yang M, Wang YH et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007; 204: 105-15.
20. Conrad C, Gregorio J, Wang YH et al. Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3 + T-Regulatory Cells. Cancer Res 2012; 72: 5240-9.
21. McCarty MF, Bielenberg D, Donawho C, Bucana CD, Fidler IJ. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 2002; 19: 609-15.
22. Faith A, Peek E, McDonald J et al. Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses. Am J Respir Cell Mol Biol 2007; 36: 360-7.
23. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008; 31: 520-7.
24. Jensen TO, Schmidt H, Moller HJ et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012; 118: 2476-85.
25. Vermi W, Bonecchi R, Facchetti F et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003; 200: 255-68.
26. Sisirak V, Faget J, Vey N et al. Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology 2013; 2: e22338.
27. Sorrentino R, Morello S, Luciano A et al. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. J Immunol 2010; 185: 4641-50.
28. Ogata M, Ito T, Shimamoto K et al. Plasmacytoid dendritic cells have a cytokine-producing capacity to enhance ICOS ligand-mediated IL-10 production during T-cell priming. Int Immunol 2013; 25: 171-82.
29. Bontkes HJ, Ruizendaal JJ, Kramer D, Meijer CJ, Hooijberg E. Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. Gynecol Oncol 2005; 96: 897-901.
30. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-51.
31. Zou T, Satake A, Corbo-Rodgers E et al. Cutting edge: IL-2 signals determine the degree of TCR signaling necessary to support regulatory T cell proliferation in vivo. J Immunol 2012; 189: 28-32.
32. Cao X, Cai SF, Fehniger TA et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27: 635-46.
33. Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-39.